GRACEcast
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Visit Show Website http://cancerGRACE.org/Recently Aired
-
HD
Do you need Avastin in first line and maintenance therapy in advanced NSCLC?
Drs. Nate Pennell, Mary Pinder, and Jack West review the ...
Drs. Nate Pennell, Mary Pinder, and Jack West review the results presented at ASCO 2013 from the PRONOUNCE trial of the ECOG 4599 trial regimen compared with carboplatin/Alimta (pemetrexed) followed by maintenance Alimta.
-
HD
Dr. Phil Bonomi: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?
Dr. Phil Bonomi, from Rush University, describes which patients with ...
Dr. Phil Bonomi, from Rush University, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
-
HD
Can we predict which patients will benefit from Tarceva based on a blood test?
Drs. Mary Pinder, Nate Pennell, and Jack West review results ...
Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.
-
HD
Drs. Ross Camidge and Corey Langer: How Do You Make Use of a Broad Molecular Profile Brought by a Patient?
Drs. Ross Camidge and Corey Langer describe their practice when ...
Drs. Ross Camidge and Corey Langer describe their practice when patients with advanced NSCLC bring them the results of broad molecular marker testing.
-
HD
Is there a role for molecular markers predicting the best chemotherapy to use in lung cancer?
Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials ...
Drs. Nate Pennell, Mary Pinder, and Jack West discuss trials presented at ASCO 2013 testing the potential value of molecular marker testing to select optimal chemo for advanced non-small cell lung cancer (NSCLC).
-
HD
Dr. Antoinette Wozniak on Small Cell Lung Cancer: Current and Future Treatments (video)
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, ...
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extensive stage small cell lung cancer, as well as emerging potential therapies.
-
HD
Dr. Antoinette Wozniak on Small Cell Lung Cancer: Current and Future Treatments (audio)
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, ...
Dr. Antoinette (Toni) Wozniak from Karmanos Cancer Center in Detroit, MI discusses the evolution of our current best treatments for limited and extensive stage small cell lung cancer, as well as emerging potential therapies.
-
HD
Is it possible to test for biomarkers in lung cancer on a national scale?
Drs. Nate Pennell, Mary Pinder, and Jack West discuss the ...
Drs. Nate Pennell, Mary Pinder, and Jack West discuss the Biomarkers France trial of testing on a national scale for clinically relevant biomarkers in advanced non-small cell lung cancer (NSCLC).
-
HD
Dr. Greg Riely: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Greg Riely, from Memorial Sloan-Kettering, provides his perspective on ...
Dr. Greg Riely, from Memorial Sloan-Kettering, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
-
HD
Dr. Geoffrey Oxnard: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, reviews his thought ...
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.
